i:X Platform’s Precise Wound Measurement, along with Fluorescence Imaging, for More Accurate Detection and Ongoing Documentation of Wounds
Toronto, CANADA – (February 20, 2020) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, released a significant upgrade to its i:X digital wound measurement feature that enables clinicians to more accurately and quickly capture digital wound area measurement. Specifically, clinicians can now reliably detect more complex wound borders using the i:X’s Auto Mode feature and can also now input a depth measurement.
“We and others have shown that standard of care length by width wound area measurements overestimate wound area measurements by more than 30%1, which is unacceptable for tracking wound progress over time”, says Danielle Dunham, Product Manager for the MolecuLight i:X platform. “With the upgrade to MolecuLight’s wound measurement feature, the device combines precise wound measurement with advanced fluorescence imaging for more accurate detection of wounds containing bacteria to empower clinicians with more information at the point of care for a more comprehensive wound assessment.”
Clinicians rely on accurate wound measurements to determine whether wounds are progressing and to evaluate the effectiveness of the treatment plan. The current standard of care involving manually measuring the length and width of wounds with a ruler leads to highly subjective, inaccurate measurements. The upgrade allows clinicians to quickly and precisely detect wound borders using MolecuLight i:X’s Auto Mode and measure wounds with greater than 95 % accuracy and with more consistency in measurements captured by different clinicians1 than manual measurement.
Using the MolecuLight i:X, clinicians simply capture an image of the wound with MolecuLight WoundStickers next to the wound. The Auto Mode feature is based on sophisticated algorithms to precisely detect and trace the wound border and then calculate wound surface area, length and width. A new optional depth input is also included so clinicians can document their wound measurements faster and spend more time focusing on treatment of the patient and their wound. See a video detailing the new i:X Digital Wound Measurement workflow.
Reference: 1Raizman, R, J Wound Care. 2019 Dec 2;28(12):824-834
About MolecuLight Inc.
MolecuLight Inc. is a privately owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s first commercially released device, the MolecuLight i:X®, and its accessories deliver a real-time handheld fluorescence imaging solution for the global wound care market. The MolecuLight i:X provides clinicians with information about the fluorescent characteristics of wounds containing bacteria to assist in making improved diagnostic and treatment decisions. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.
MolecuLight operates worldwide through its Headquarters and subsidiaries in various countries including MolecuLight Inc. (Canada), MolecuLight Corp. (USA), MolecuLight GmbH (Germany), MolecuLight France, MolecuLight UK Ltd., MolecuLight Italy S.R.L., and MolecuLight Holland B.V.
Each of these entities is supported by local MolecuLight Sales and Clinical Applications teams who support customers by providing clinical demonstrations, by delivering MolecuLight’s comprehensive training program and by supportingthe ongoing adoption of the i:X device.
For further information, please contact:
Chief Marketing Officer